SCHEMBL1856293

SCHEMBL1856293

Cc1sc2cccc(C)c2c1B(O)O

nearest known ligand 0.35

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.33
PLAU P00749 1/20 0.33
MAPT P10636 1/20 0.32
MGLL Q99685 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2387694 0.74 ALDH1A1 (0.38) ALDH1A1PLAUMAPT
SCHEMBL498434 0.73 MAPT (0.46) ALDH1A1MAPTMGLL
SCHEMBL4160530 0.73 ALDH1A1 (0.43) ALDH1A1PLAUMAPT
SCHEMBL61913 0.72 ALDH1A1 (0.50) ALDH1A1
SCHEMBL14154413 0.71 MAPK1 (0.37) ALDH1A1PLAUMAPT
SCHEMBL1856296 0.70 CYP2A6 (0.38) ALDH1A1PLAUMAPT
SCHEMBL20694978 0.70 ALDH1A1 (0.48) ALDH1A1
SCHEMBL28221318 0.70 ALDH1A1 (0.48) ALDH1A1
SCHEMBL6130179 0.68 CYP2A6 (0.44) ALDH1A1PLAUMAPT
SCHEMBL15595450 0.68 LIMK1 (0.41) ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1609785-B1 C-GLYCOSIDE DERIVATIVES AND SALTS THEREOF ASTELLAS PHARMA INC (JP) 2016-02-03 EP disclosed
US-7977466-B2 C-glycoside derivatives and salts thereof ASTELLAS PHARMA INC. (JP) 2011-07-12 US disclosed
EP-1980560-B1 C-glycoside derivatives for the treatment of diabetes ASTELLAS PHARMA INC (JP) 2011-05-25 EP disclosed
US-7772407-B2 C-glycoside derivatives and salts thereof ASTELLAS PHARMA INC. (JP) 2010-08-10 US disclosed
US-20090069252-A1 C-GLYCOSIDE DERIVATIVES AND SALTS THEREOF ASTELLAS PHARMA INC. (JP) 2009-03-12 US disclosed
EP-1980560-A2 C-glycoside derivatives for the treatment of diabetes Astellas Pharma Inc. (JP) 2008-10-15 EP disclosed
US-20070161787-A1 C-glycoside derivatives and salts thereof ASTELLAS PHARMA INC. (JP) 2007-07-12 US disclosed
US-7202350-B2 C-glycoside derivatives and salts thereof ASTELLAS PHARMA INC. (JP) 2007-04-10 US disclosed
US-20060122126-A1 C-glycoside derivatives and salts thereof ASTELLAS PHARMA INC. (JP) 2006-06-08 US disclosed
EP-1609785-A1 C-GLYCOSIDE DERIVATIVES AND SALTS THEREOF Astellas Pharma Inc. (JP) 2005-12-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161787-A1 C-glycoside derivatives and salts thereof SLC5A1, SLC5A2, SLC2A1 ALDH1A1 1354/4885PLAU 4382/4885MAPT 4233/4885
US-20060122126-A1 C-glycoside derivatives and salts thereof SLC5A1, SLC5A2, SLC2A1 ALDH1A1 1354/4885PLAU 4382/4885MAPT 4233/4885
US-20090069252-A1 C-GLYCOSIDE DERIVATIVES AND SALTS THEREOF SLC5A1, SLC5A2, SLC2A1 ALDH1A1 1354/4885PLAU 4382/4885MAPT 4233/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.